‘The UK is still early compared to other international medical cannabis markets, but has huge potential.’
Speaking on CIC’s newest guidance report, Travelling With Medical Cannabis
Adam Windish is CEO of BRITISH CANNABIS™, one of the UK’s leading cannabinoid companies, where he leads strategy, revenue, and the expansion of both medical and over the counter product lines.
He has played a key role in scaling distribution, building white label partnerships, and bringing new cannabinoid products to market across the UK and international markets. His work sits at the intersection of regulation, product development, and patient access, with a focus on building commercially viable pathways in a highly regulated environment.
Alongside his commercial role, Adam serves as the Cannabis Industry Council’s pillar lead for education, awareness, and standards, contributing to the development of clearer frameworks and guidance across the sector.
He regularly speaks on market development, regulation, and the future of medical cannabis in the UK and internationally.
On the London 2026 programme
- Day 2 · The Greenhouse · 10:45 amTravelling with Medical Cannabis: Navigating Legal Complexity Across Borders